Evidence map›Paper›PMID 32451824›Full record

ArticleJournal of thrombosis and thrombolysis2020

National trends in tranexamic acid use in the peripartum period, 2015-2019.

Homa K Ahmadzia, Elaine B Hynds, Richard L Amdur, Alexis C Gimovsky, Andra H James, Naomi L C Luban

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Homa K AhmadziaDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The George Washington University, 2150 Pennsylvania Avenue, Washington, D.C., 20037, USA. hahmadzia@mfa.gwu.edu.
Elaine B HyndsSchool of Medicine and Health Sciences, George Washington University, Washington, D.C., USA.
Richard L AmdurDepartment of Biostatistics, George Washington University, Washington, D.C., USA.
Alexis C GimovskySchool of Medicine and Health Sciences, George Washington University, Washington, D.C., USA.
Andra H JamesDivision of Maternal Fetal Medicine, Duke University, Durham, NC, USA.
Naomi L C LubanDivision of Pathology, Children's National Hospital, Washington, D.C., USA.
George Washington University · USChildren's National · USDuke University · US

Funding

Prevention of postpartum hemorrhage: identifying pregnant women at risk and determining the safe and effective use of tranexamic acid using state-of-the-art pharmacokinetic/pharmacodynamics modelingK23HL141640 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI AHMADZIA, HOMA KHORRAMI · 2019 to 2022
$621k
NHLBI NIH HHS K23 HL141640NHLBI NIH HHS K23HL141640
6 · The paper itself

Abstract

backgroundThe purpose of this study was to measure trends in the use of tranexamic acid (TXA) during delivery in the United States and to evaluate demographic data and morbidity outcomes among these patients.

methodsThis retrospective cohort study includes data from 19 hospitals in the Universal Health Services network. We compared rates of TXA use between January 2015 and June 2019 across geographic sectors. We also evaluated associations of demographic variables and perinatal outcomes of women who received TXA.

results209 cases of TXA use were found from analysis of 101,564 deliveries. TXA use increased over time and rates were higher in the West than in Central and East; the slope of increase over years did not differ between regions. Women who received TXA were more likely to have a history of postpartum hemorrhage (59 (28.2%) vs. 2290 (2.2%), P < 0.0001) but were not more likely to have a chronic disease, including diabetes mellitus, hypertension and heart disease. Women who received TXA were more likely to have estimated blood loss greater than or equal to 1000 mL (adjusted odds ratio (aOR) 15.3; 95% CI 11.1-21.1; P < 0.0001). Likelihood of venous thromboembolism was not significantly increased in TXA recipients (aOR 2.0; 95% CI 0.3-14.6; P = 0.49).

conclusionIncreasing national trends of TXA use in the peripartum period was observed, with variable increases by geographic region. Likelihood of venous thromboembolism was not significantly increased among women who received TXA. Increasing TXA use throughout the country suggests that updated hemorrhage guidelines from national obstetrical organizations can shape clinical practice.

Indexed as

AdultAntifibrinolytic AgentsFemaleHumansPeripartum PeriodPostpartum HemorrhagePregnancyPregnancy Complications, CardiovascularRetrospective StudiesTranexamic AcidUnited StatesVenous ThromboembolismYoung AdultAntifibrinolytic AgentsTranexamic AcidPerinatal outcomesPostpartum hemorrhageTranexamic acidVenous thromboembolism

Identifiers

PMID32451824
PMCPMC7529751
OpenAlexW3028706274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.